Wednesday Feb 26
FDA Approves Orphan Drug Myalept
AstraZeneca announced FDA approved orphan drug Myalept , which is indicated as an adjunct to diet as replacement therapy for the treatment of complications of leptin deficiency in patientswith congenital or acquired generalized lipodystrophy.
Amylin Pharmaceuticals Partnering 2005-2013 - new company profile report published
The Partnering Agreements with Amylin Pharmaceuticals 2005-2013 report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.
Ambit Biosciences Appoints To Board Of Directors
"His significant experience in the pharmaceutical industry combined with his strong financial background and leadership role on the audit committee will be great assets as we move forward with the clinical development of our lead drug candidate, quizartinib, and our pipeline of kinase inhibitors."
The Washington Post
Bristol-Myers Still Willing to Take Deal Bets Despite Two Misses
Bristol-Myers Squibb Co. will continue to seek out innovative drugs to buy, particularly for cancer, shrugging off two previous deals totaling $7.8 billion in the last three years that failed to pay off for them.